SCHEMBL20548415

SCHEMBL20548415

O=c1snc(Cc2c(F)cccc2Cl)n1CC1CCCCC1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALOX15 P16050 3/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ BRCA1 P38398 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ HBB P68871 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ DAO P14920 1/20 0.36
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30314375 1.00 LMNA (0.41) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL30314317 0.89 LMNA (0.39) LMNAALDH1A1DAOADORA2AADORA2B
SCHEMBL20548443 0.89 LMNA (0.39) LMNAALDH1A1DAOADORA2AADORA2B
SCHEMBL20548470 0.80 P2RX7 (0.44) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL29195836 0.80 ADORA2A (0.43) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL20548629 0.80 P2RX7 (0.44) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL30314271 0.80 P2RX7 (0.44) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL29195852 0.80 ADORA2A (0.43) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL30314291 0.80 P2RX7 (0.44) LMNAALDH1A1KDM4EALOX15CASP1
SCHEMBL20548580 0.80 LMNA (0.41) LMNAALDH1A1MAPTKMT2ADAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110770214-B Heterocyclic P2X7 antagonists 布雷耶疗法有限公司 2024-03-29 — — CN claimed
EP-3619200-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2020-03-11 — — EP claimed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 — — US claimed
CN-110770214-A Heterocyclic P2X7 antagonists 阿克萨姆股份公司 2020-02-07 — — CN claimed
WO-2018202694-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.P.A. (IT) 2018-11-08 — — WO claimed
EP-3398941-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2018-11-07 — — EP claimed
US-11623919-B2 Heterocyclic P2X7 antagonists BREYE THERAPEUTICS APS (DK) 2023-04-11 — — US disclosed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 — — US disclosed
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 — — US disclosed
EP-3398941-A1 HETEROCYCLIC P2X7 ANTAGONISTS AXXAM S.p.A. (IT) 2018-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS P2RY1, P2RX1, P2RX3 LMNA 2079/4885ALDH1A1 1689/4885KDM4E 4268/4885
US-11623919-B2 Heterocyclic P2X7 antagonists P2RY1, P2RX1, P2RX3 LMNA 2079/4885ALDH1A1 1689/4885KDM4E 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback